Dasatinib for HIV-1 Reservoir Reduction

Conditions

• HIV Infections

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dasatinib — DRUG
  will be administered as one 100 mg capsule (over-encapsulated tablet) orally once daily for 12 weeks
• Placebo — OTHER
  Placebo for dasatinib will be administered as one placebo capsule (over-encapsulated tablet) orally once daily for 12 weeks

Study Details

This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or older who have been on ART for at least 48 months and have had a suppressed HIV-1 viral load for at least 36 months may be able to join. People will be randomly assigned to take dasatinib 100 mg by mouth once a day or a look-alike substance with no drug, called a placebo, for 12 weeks. Neither participants nor researchers will know who gets which (double-blind). The study team will do regular health checks and blood tests to track safety, tolerability, the HIV reservoir, and changes in immune cells. The study lasts 36 weeks total: 12 weeks of treatment and 24 weeks of follow-up, with clinic visits and possible phone calls. Fourteen people will take part; eight will get dasatinib and six will get placebo. Dasatinib may lower the HIV reservoir, but this is not guaranteed. All medicines can cause side effects, called adverse events (AE). The study team will watch closely and provide medical support. Joining is your choice, and you can leave at any time. If you leave, the team will talk with you about next steps for your care.

Key Dates

Start date

May 8, 2026

Status verified

Jun 2026

Primary completion

Nov 25, 2026

Completion

May 12, 2027

Study Design

Enrollment

14 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm 1: dasatinib
  100 mg by mouth daily
• Placebo Comparator: Arm 2: Placebo
  Placebo for dasatinib

Primary Outcome Measure

Change in intact HIV-1 reservoir size [ Time Frame: Baseline and week 12 ]

Locations (3)

Find similar trials in Chicago, IL

Related Studies

• HIV Prevention Among At-risk Latinos in the Heartland
  Enrolling By Invitation · Medical College of Wisconsin · Indianapolis, Indiana
• Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests
  Recruiting · University of Washington · Seattle, Washington
• Keeping it LITE: Exploring HIV Risk in Vulnerable Youth With Limited Interaction and Digital Health Intervention
  Recruiting · Hektoen Institute for Medical Research · Chicago, Illinois
• Screen Smart: Using Digital Health to Improve HIV Screening and Prevention
  Recruiting · Children's Hospital Medical Center, Cincinnati · Columbus, Ohio